Although numerous molecules, including thyroid hormone receptors β (THRβ) and fibroblast growth factor 21 (FGF21), have been tested as potential targets for treating MASLD, few have demonstrated sufficient efficacy or acceptable side-effect profiles 2. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.